Current Oncology · 2021 · 13 citations · 7 references
MedicineOncologyPharmacologyCancer ImmunologyImmunopathologyImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune CheckpointsImmune-related Adverse EventsTreatment DurationAcute Hepatitis ManagementCheckpoint Inhibitor HepatitisCheckpoint Inhibitor Toxicity ManagementEarly Toxicity RecognitionImmune Checkpoint MonitoringImmune-mediated Adverse EventsMonitoring During Immune Checkpoint TherapyPembrolizumab Therapy
Immune checkpoint inhibitors (ICIs) have led to major therapeutic advances in the management of malignancy. Despite promising outcomes for some cancers, ICIs are linked to unique side-effects known as immune-related adverse events (IrAEs). These may affect a wide array of organ systems. In particular, ICI-induced hepatitis is diagnostically challenging given its variable natural history and clinical manifestations. The onset of ICI-induced hepatitis often occurs between 6 and 14 weeks after treatment initiation and rarely exhibits delayed presentations or manifests after treatment cessation. We present a case of very delayed-onset ICI-induced hepatitis, stressing the importance of long-term surveillance for immune-indued hepatitis in patients initiated on ICIs even long after treatment cessation.
7
Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril et al. · Cancer · 2013 · 461 citations
Medicine, Oncology, Pharmacology +17
Julie R. Brahmer, Christina Lacchetti, John A. Thompson · Journal of Oncology Practice · 2018 · 373 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +16
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim, Nikhil H. Ramaiya, Katherine M. Krajewski et al. · Investigational New Drugs · 2013 · 233 citations
Medicine, Immunology, Pathology +12